Targeting Cdc42 in cancer
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: The Rho GTPases are a family of proteins that control fundamental cellular processes in response to extracellular stimuli and internal programs. Rho GTPases function as molecular switches in which the GTP-bound proteins are active and GDP-bound proteins are inactive. This article will focus on one Rho family member, Cdc42, which is overexpressed in a number of human cancers, and which might provide new therapeutic targets in malignancies. AREAS COVERED: In this article, the key regulators and effectors of Cdc42 and their molecular alterations are described. The complex interactions between the signaling cascades regulated by Cdc42 are also analyzed. EXPERT OPINION: While mutations in Cdc42 have not been reported in human cancer, aberrant expression of Cdc42 has been reported in a variety of tumor types and in some instances has been correlated with poor prognosis. Recently, it has been shown that Cdc42 activation by oncogenic Ras is crucial for Ras-mediated tumorigenesis, suggesting that targeting Cdc42 or its effectors might be useful in tumors harboring activating Ras mutations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
The ‘invisible hand’: Regulation of RHO GTPases by RHOGDIs
Garcia-Mata, R., Boulter, E., & Burridge, K. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3153 · Cited by 560
Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity.
Mahajan, K., Challa, S., Coppola, D., Lawrence, H., Luo, Y., Gevariya, H., Zhu, W., Chen, Y. A., Lawrence, N. J., & Mahajan, N. P. (2010) · The Prostate · doi:10.1002/pros.21163 · Cited by 86
Cited by
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Glaviano, A., Foo, A. S. C., Lam, H. Y., Yap, K. C. H., Jacot, W., Jones, R. H., Eng, H., Nair, M. G., Makvandi, P., Geoerger, B., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01827-6 · Cited by 2,138
A Systematic Review of miR-29 in Cancer
Kwon, J. J., Factora, T. D., Dey, S., & Kota, J. (2019) · Molecular Therapy Oncolytics · doi:10.1016/j.omto.2018.12.011 · Cited by 263
Targeting Rac and Cdc42 GTPases in Cancer
Maldonado, M. D. M., & Dharmawardhane, S. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0619 · Cited by 237
“Therefore, targeting Cdc42 is also considered a viable option for cancer therapy (6).”
BackgroundDeregulation of Rho GTPases in cancer
Porter, A. P., Papaioannou, A., & Malliri, A. (2016) · Small GTPases · doi:10.1080/21541248.2016.1173767 · Cited by 194
“sue, both increased and decreased, compared to normal tissue.(36) Cdc42 is overexpressed in testicular and breast cancer,(15,16,37) in non-small cell lung cancer,(38) and in colorectal adenocarcinoma and cutaneous melanoma.”
BackgroundFunctional dysregulation of CDC42 causes diverse developmental phenotypes
Martinelli, S., Krumbach, O. H. F., Pantaleoni, F., Coppola, S., Amin, E., Pannone, L., Nouri, K., Farina, L., Dvorsky, R., Lepri, F., et al. (2018) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2017.12.015 · Cited by 188
Metadata
- Authors
- Arias-Romero, L. E., & Chernoff, J.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa UK Limited
- Published
- 2013-08-19
- Volume
- 17
- Issue
- 11
- Pages
- 1263-1273
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W2104010628
- Cited by
- 79
- References
- 3
- FWCI
- 2.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.